Hemostasis requires both platelets and the coagulation system. At sites of vessel injury,
bleeding is minimized by the formation of a hemostatic plug consisting of platelets and fibrin …

The classic intrinsic pathway of coagulation is triggered by contact activation of the plasma
protease factor (F) XII, followed by sequential proteolytic activation of FX1 and FIX. While a …

The pathogenesis of hypercoagulability in cancer is not entirely understood. We
hypothesized that in cancer patients circulating tissue factor-positive microparticles (TF+ …

The source and significance of bloodborne tissue factor (TF) are controversial. TF mRNA,
protein, and TF-dependent procoagulant activity (PCA) have been detected in human …

Thrombus formation, including platelet adhesion, activation, secretion and aggregation as
well as tissue factor-initiated thrombin generation and fibrin formation, has been studied in …

Thrombotic complications of vascular disease are the leading cause of morbidity and
mortality in most industrialized countries. Despite this, safe and effective drugs targeting …

Adhesion of platelets to an injured vessel wall and platelet activation are critical events in
the formation of a thrombus. Of the agonists involved in platelet activation, thrombin …

There is strong evidence linking venous thromboembolic events and malignancy.
Laboratory markers of coagulation activation such as thrombin–antithrombin complex or …

Platelets play a central role in hemostasis, but also in atherothrombosis, as they rapidly
adhere to tissue and to one another as a response to any vascular injury. This process …

Context: Type 2 diabetes mellitus (T2DM) is a hypercoagulable state. Tissue factor (TF) is
the principal initiator of blood coagulation. Objective: Our objective was to examine the …